The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection

The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection

Bibliographic Details
Main Authors: C. Gay, J.D. Kuruc, S.D. Falcinelli, J. Warren, J.L. Kirchherr, K. Sholtis, B. Allard, E. Stuelke, A. Gamble, A. Plachco, I. Tcherapanova, J.J. Eron, N. Goonetilleke, M. DeBenedette, C.A. Nicolette, N.M. Archin, D.M. Margolis
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Journal of Virus Eradication
Online Access:http://www.sciencedirect.com/science/article/pii/S2055664020310670
id doaj-e5e7c642c977418ab426a4f6ff5ef76e
record_format Article
spelling doaj-e5e7c642c977418ab426a4f6ff5ef76e2021-05-05T04:07:24ZengElsevierJournal of Virus Eradication2055-66402019-07-01523The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 InfectionC. Gay0J.D. Kuruc1S.D. Falcinelli2J. Warren3J.L. Kirchherr4K. Sholtis5B. Allard6E. Stuelke7A. Gamble8A. Plachco9I. Tcherapanova10J.J. Eron11N. Goonetilleke12M. DeBenedette13C.A. Nicolette14N.M. Archin15D.M. Margolis16UNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USADepartment of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USAArgos Therapeutics, Durham, NC, USAArgos Therapeutics, Durham, NC, USAArgos Therapeutics, Durham, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAArgos Therapeutics, Durham, NC, USAArgos Therapeutics, Durham, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAUNC Chapel Hill HIV Cure Center, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USAhttp://www.sciencedirect.com/science/article/pii/S2055664020310670
collection DOAJ
language English
format Article
sources DOAJ
author C. Gay
J.D. Kuruc
S.D. Falcinelli
J. Warren
J.L. Kirchherr
K. Sholtis
B. Allard
E. Stuelke
A. Gamble
A. Plachco
I. Tcherapanova
J.J. Eron
N. Goonetilleke
M. DeBenedette
C.A. Nicolette
N.M. Archin
D.M. Margolis
spellingShingle C. Gay
J.D. Kuruc
S.D. Falcinelli
J. Warren
J.L. Kirchherr
K. Sholtis
B. Allard
E. Stuelke
A. Gamble
A. Plachco
I. Tcherapanova
J.J. Eron
N. Goonetilleke
M. DeBenedette
C.A. Nicolette
N.M. Archin
D.M. Margolis
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
Journal of Virus Eradication
author_facet C. Gay
J.D. Kuruc
S.D. Falcinelli
J. Warren
J.L. Kirchherr
K. Sholtis
B. Allard
E. Stuelke
A. Gamble
A. Plachco
I. Tcherapanova
J.J. Eron
N. Goonetilleke
M. DeBenedette
C.A. Nicolette
N.M. Archin
D.M. Margolis
author_sort C. Gay
title The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
title_short The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
title_full The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
title_fullStr The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
title_full_unstemmed The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
title_sort impact of vorinostat and ags-004, a dendritic cell-based immunotherapy, on persistent hiv-1 infection
publisher Elsevier
series Journal of Virus Eradication
issn 2055-6640
publishDate 2019-07-01
url http://www.sciencedirect.com/science/article/pii/S2055664020310670
work_keys_str_mv AT cgay theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jdkuruc theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT sdfalcinelli theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jwarren theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jlkirchherr theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT ksholtis theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT ballard theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT estuelke theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT agamble theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT aplachco theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT itcherapanova theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jjeron theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT ngoonetilleke theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT mdebenedette theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT canicolette theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT nmarchin theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT dmmargolis theimpactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT cgay impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jdkuruc impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT sdfalcinelli impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jwarren impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jlkirchherr impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT ksholtis impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT ballard impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT estuelke impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT agamble impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT aplachco impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT itcherapanova impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT jjeron impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT ngoonetilleke impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT mdebenedette impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT canicolette impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT nmarchin impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
AT dmmargolis impactofvorinostatandags004adendriticcellbasedimmunotherapyonpersistenthiv1infection
_version_ 1721475649812561920

Similar Items